Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Retained Earnings data on record, last reported at -$1.2 billion in Q3 2025.

  • For Q3 2025, Retained Earnings fell 32.96% year-over-year to -$1.2 billion; the TTM value through Sep 2025 reached -$1.2 billion, down 32.96%, while the annual FY2024 figure was -$995.9 million, 294732.25% down from the prior year.
  • Retained Earnings reached -$1.2 billion in Q3 2025 per VRDN's latest filing, down from -$1.2 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $338000.0 in Q4 2023 and bottomed at -$1.2 billion in Q3 2025.
  • Average Retained Earnings over 5 years is -$422.3 million, with a median of -$315.3 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: crashed 14746200.0% in 2022, then surged 186.67% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$157000.0 in 2021, then tumbled by 148.41% to -$390000.0 in 2022, then soared by 186.67% to $338000.0 in 2023, then plummeted by 294732.25% to -$995.9 million in 2024, then dropped by 22.32% to -$1.2 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.2 billion in Q3 2025, -$1.2 billion in Q2 2025, and -$1.1 billion in Q1 2025.